In March 2006, six healthy volunteers of a Phase I clinical trial who had received a single infusion of the CD28 superagonistic antibody TGN1412 suffered unpredicted devastating effects that left ...

In 2006, a human trial on the leukemia drug theralizumab (TGN1412) resulted in high cytokine levels and organ failure in healthy volunteers, despite preclinical studies finding no evidence of ...